Literature DB >> 23334858

The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland.

Wojciech Kluźniak1, Dominika Wokołorczyk, Aniruddh Kashyap, Anna Jakubowska, Jacek Gronwald, Tomasz Huzarski, Tomasz Byrski, Tadeusz Dębniak, Adam Gołąb, Bartłomiej Gliniewicz, Andrzej Sikorski, Jerzy Switała, Tomasz Borkowski, Andrzej Borkowski, Andrzej Antczak, Lukasz Wojnar, Jacek Przybyła, Marek Sosnowski, Bartosz Małkiewicz, Romuald Zdrojowy, Paulina Sikorska-Radek, Józef Matych, Jacek Wilkosz, Waldemar Różański, Jacek Kiś, Krzysztof Bar, Piotr Bryniarski, Andrzej Paradysz, Konrad Jersak, Jerzy Niemirowicz, Piotr Słupski, Piotr Jarzemski, Michał Skrzypczyk, Jakub Dobruch, Paweł Domagała, Mohammad R Akbari, Jan Lubiński, Steven A Narod, Cezary Cybulski.   

Abstract

BACKGROUND: The G84E mutation in the HOXB13 gene has been associated with a high lifetime risk of prostate cancer in North America (about 20-fold). The geographical and ethnic extent of this recurrent allele has not yet been determined.
METHODS: We assayed for the presence of the G84E mutation in 3,515 prostate cancer patients and 2,604 controls from Poland and estimated the odds ratio for prostate cancer associated with the allele.
RESULTS: The G84E mutation was detected in 3 of 2,604 (0.1%) individuals from the general population in Poland and in 20 of 3,515 (0.6%) men with prostate cancer (Odds ratio [OR] = 5.0; 95% CI: 1.5-16.7; P = 0.008). The allele was present in 4 of 416 (1.0%) men with familial prostate cancer (OR = 8.4, 95% CI: 1.9-37.7; P = 0.005).
CONCLUSIONS: The G84E mutation predisposes to prostate cancer in Poland, but accounts for only a small proportion of cases. We expect that the G84E founder mutation might be present in other Slavic populations.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334858     DOI: 10.1002/pros.22594

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  23 in total

1.  G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis.

Authors:  Hang Huang; Bing Cai
Journal:  Tumour Biol       Date:  2013-09-13

2.  Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.

Authors:  Wei Sheng; Hongwei Zhang; Yong Lu
Journal:  Int Urol Nephrol       Date:  2018-07-07       Impact factor: 2.370

3.  The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.

Authors:  Jennifer L Beebe-Dimmer; Matthew Hathcock; Cecilia Yee; Linda A Okoth; Charles M Ewing; William B Isaacs; Kathleen A Cooney; Stephen N Thibodeau
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-24       Impact factor: 4.254

Review 4.  Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Authors:  Veda N Giri; Karen E Knudsen; William K Kelly; Wassim Abida; Gerald L Andriole; Chris H Bangma; Justin E Bekelman; Mitchell C Benson; Amie Blanco; Arthur Burnett; William J Catalona; Kathleen A Cooney; Matthew Cooperberg; David E Crawford; Robert B Den; Adam P Dicker; Scott Eggener; Neil Fleshner; Matthew L Freedman; Freddie C Hamdy; Jean Hoffman-Censits; Mark D Hurwitz; Colette Hyatt; William B Isaacs; Christopher J Kane; Philip Kantoff; R Jeffrey Karnes; Lawrence I Karsh; Eric A Klein; Daniel W Lin; Kevin R Loughlin; Grace Lu-Yao; S Bruce Malkowicz; Mark J Mann; James R Mark; Peter A McCue; Martin M Miner; Todd Morgan; Judd W Moul; Ronald E Myers; Sarah M Nielsen; Elias Obeid; Christian P Pavlovich; Stephen C Peiper; David F Penson; Daniel Petrylak; Curtis A Pettaway; Robert Pilarski; Peter A Pinto; Wendy Poage; Ganesh V Raj; Timothy R Rebbeck; Mark E Robson; Matt T Rosenberg; Howard Sandler; Oliver Sartor; Edward Schaeffer; Gordon F Schwartz; Mark S Shahin; Neal D Shore; Brian Shuch; Howard R Soule; Scott A Tomlins; Edouard J Trabulsi; Robert Uzzo; Donald J Vander Griend; Patrick C Walsh; Carol J Weil; Richard Wender; Leonard G Gomella
Journal:  J Clin Oncol       Date:  2017-12-13       Impact factor: 44.544

5.  Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer.

Authors:  Kimberly A Zuhlke; Anna M Johnson; Scott A Tomlins; Nallasivam Palanisamy; John D Carpten; Ethan M Lange; William B Isaacs; Kathleen A Cooney
Journal:  Prostate       Date:  2014-05-06       Impact factor: 4.104

6.  Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer.

Authors:  Elizabeth Handorf; Nicole Crumpler; Laura Gross; Veda N Giri
Journal:  J Genet Couns       Date:  2013-12-07       Impact factor: 2.537

Review 7.  Prostate cancer in young men: an important clinical entity.

Authors:  Claudia A Salinas; Alex Tsodikov; Miriam Ishak-Howard; Kathleen A Cooney
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

8.  Prostate cancer risk-associated genetic markers and their potential clinical utility.

Authors:  Jianfeng Xu; Jielin Sun; S Lilly Zheng
Journal:  Asian J Androl       Date:  2013-04-08       Impact factor: 3.285

9.  HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.

Authors:  Steven C Smith; Nallasivam Palanisamy; Kimberly A Zuhlke; Anna M Johnson; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju; Kathleen A Cooney; Scott A Tomlins
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

10.  A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.

Authors:  C Cybulski; D Wokołorczyk; W Kluźniak; A Kashyap; A Gołąb; M Słojewski; A Sikorski; M Puszyński; M Soczawa; T Borkowski; A Borkowski; A Antczak; J Przybyła; M Sosnowski; B Małkiewicz; R Zdrojowy; P Domagała; K Piotrowski; J Menkiszak; K Krzystolik; J Gronwald; A Jakubowska; B Górski; T Dębniak; B Masojć; T Huzarski; K R Muir; A Lophatananon; J Lubiński; S A Narod
Journal:  Br J Cancer       Date:  2013-05-30       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.